Simon J. Dovedi

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Innovative strategies for T cell engagers for cancer immunotherapy.

Innovative strategies for T cell engagers for cancer immunotherapy.

Journal: mAbs
Published: July 11, 2025

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.

Journal: Journal for immunotherapy of cancer
Published: July 07, 2025

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.

Journal: Scientific reports
Published: May 01, 2025

A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical research.

A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical research.

Journal: Frontiers in immunology
Published: April 24, 2025

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.

Journal: Journal for immunotherapy of cancer
Published: March 16, 2025

In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade.

In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade.

Journal: Cancer immunology research
Published: December 03, 2024

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.

Journal: mAbs
Published: August 29, 2024

Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction.

Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction.

Journal: Cell reports
Published: May 09, 2024

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.

Journal: Cancer biology & therapy
Published: January 11, 2024

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity.

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity.

Journal: Nature communications
Published: July 20, 2023

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.

Journal: Journal for immunotherapy of cancer
Published: July 16, 2023

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.

Journal: Frontiers in immunology
Published: July 13, 2023
Showing 1-12 of 55

Last Updated: 09/26/2026